Product Description
U-500R Insulin for Type 2 Diabetes
Mechanisms of Action: INSR Binder
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Type 2 Diabetes
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Type 2 Diabetes|Type 1 Diabetes|Tobacco Use Disorder
Phase 2: Type 1 Diabetes|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02588950 |
B5K-EW-IBHG | P1 |
Terminated |
Type 2 Diabetes |
2017-05-25 |
2023-10-19 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT00063128 |
H7U-MC-IDAI | P2 |
Completed |
Type 1 Diabetes |
None |
2020-10-26 |
Primary Endpoints|Treatments |
|
NCT00099515 |
IDAP | P2 |
Completed |
Type 2 Diabetes |
None |
2019-03-21 |
Treatments |
|
NCT02561078 |
VIVID | P3 |
Completed |
Type 2 Diabetes |
2017-05-09 |
2020-05-21 |
Primary Endpoints|Start Date|Treatments |
|
NCT00355849 |
H7U-MC-IDBA | P3 |
Completed |
Type 2 Diabetes |
2008-06-01 |
2019-03-21 |
||
2006-000247-26 |
IDBA | P3 |
Terminated |
Type 2 Diabetes|Tobacco Use Disorder |
2008-05-30 |
2022-03-12 |
Treatments |
|
2005-004747-64 |
IDAU | P3 |
Terminated |
Type 2 Diabetes |
2008-05-28 |
2022-03-12 |
Treatments |
|
2006-002999-17 |
IDAY | P3 |
Completed |
Tobacco Use Disorder|Type 2 Diabetes |
2008-05-12 |
2022-03-12 |
Treatments |
|
NCT00127634 |
H7U-MC-IDAH | P3 |
Completed |
Type 1 Diabetes |
2008-05-01 |
2019-03-21 |
||
NCT00325364 |
H7U-MC-IDAU | P3 |
Completed |
Type 2 Diabetes |
2008-05-01 |
2019-03-21 |
Treatments |
|
NCT00447213 |
H7U-JE-IDBB | P3 |
Completed |
Type 1 Diabetes |
2008-05-01 |
2019-03-21 |
Treatments |
|
NCT00437112 |
H7U-MC-IDAZ | P3 |
Completed |
Type 2 Diabetes |
2008-05-01 |
2019-03-21 |
Treatments |
|
NCT00157339 |
H7U-MC-IDAS | P3 |
Completed |
Asthma|Chronic Obstructive Pulmonary Disease |
2008-05-01 |
2019-03-21 |
Treatments |
|
NCT00356109 |
H7U-MC-IDAV | P3 |
Completed |
Type 1 Diabetes |
2008-05-01 |
2019-03-21 |
Treatments |
|
NCT00391209 |
H7U-MC-IDAY | P3 |
Completed |
Type 2 Diabetes |
2008-05-01 |
2019-03-21 |
Treatments |
|
NCT00490854 |
H7U-JE-IDBF | P3 |
Completed |
Type 2 Diabetes |
2008-05-01 |
2019-03-21 |
Treatments |
|
2006-000497-80 |
IDAV | P3 |
Completed |
Type 1 Diabetes|Tobacco Use Disorder |
2008-01-27 |
2022-03-12 |
Treatments |
|
2005-005381-37 |
IDAW | P3 |
Terminated |
Type 2 Diabetes|Tobacco Use Disorder |
2008-01-05 |
2022-03-12 |
Treatments |
|
NCT01774968 |
B5K-US-IBHC | P4 |
Completed |
Type 2 Diabetes |
2014-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|